ArticleLeukemia & lymphoma2017

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Douglas W Sborov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.